March 29, 2018 / 6:19 AM / 6 months ago

BRIEF-Shire ‍says EMA has validated its marketing authorization application for Lanadelumab

March 29 (Reuters) - Shire Plc:

* ‍ANNOUNCED EUROPEAN MEDICINES AGENCY HAS VALIDATED ITS MARKETING AUTHORIZATION APPLICATION FOR LANADELUMAB (SHP643)​

* ‍REPORTS THAT HEALTH CANADA HAS COMPLETED SCREENING AND ACCEPTED NEW DRUG SUBMISSION UNDER PRIORITY REVIEW FOR INVESTIGATIONAL COMPOUND​

* ‍HEALTH CANADA'S RECENT ACCEPTANCE OF LANADELUMAB NDS FOR PRIORITY REVIEW SHORTENS REVIEW TIMELINE FROM 300 TO 180 DAYS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below